The US Food and Drug Administration has authorized the Pfizer and BioNTech coronavirus vaccine for children aged 5 to 11 years, making it the first COVID-19 shot for young children in the United States.
The shot will not be immediately available to the age group. The US Centers for Disease Control and Prevention still needs to advise on how the shot should be administered, which will be decided after a group of outside advisers discuss the plan on Tuesday.
Pfizer said it will begin shipping pediatric vials of the vaccine on Saturday to pharmacies, pediatricians’ offices and other places where the shots may be administered.
The FDA decision is expected to make the vaccine available to 28 million American children, many of whom are back in school for in-person learning.
It comes after a panel of advisers to the regulator voted overwhelmingly to recommend the authorization on Tuesday.
Only a few other countries, including China, Cuba and the United Arab Emirates, have so far cleared COVID-19 vaccines for children in this age group and younger.
The FDA authorized a 10-microgram dose of Pfizer’s vaccine in young children, lower than the 30 micrograms in the original vaccine for those age 12 and older.
Advisers on the FDA panel said a lower dose could help mitigate some of the rare side effects after paying close attention to the rate of heart inflammation, or myocarditis, that has been linked to both Pfizer and Moderna vaccines, especially in young men.
The regulator said that known and potential benefits of the Pfizer vaccine in individuals aged between 5 and 11 outweigh the risks.
In the United States, around 58% of the population is fully vaccinated, lagging other nations such as the UK and France. Many adults, who have been hesitant to get a vaccine, may be more cautious about giving the shot to their children.
